These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Drugs for treatment of peptic ulcers. Dajani EZ; Trotman BW J Assoc Acad Minor Phys; 1992; 3(3):78-88. PubMed ID: 1353999 [TBL] [Abstract][Full Text] [Related]
6. Pharmacological management of patients with peptic ulcer disease: prospects for the late 1980's. Thomson AB; Mahachai V Clin Invest Med; 1987 May; 10(3):152-70. PubMed ID: 2887321 [TBL] [Abstract][Full Text] [Related]
7. Problems associated with medical treatment of peptic ulcer disease. Zimmerman TW Am J Med; 1984 Nov; 77(5B):51-6. PubMed ID: 6095662 [TBL] [Abstract][Full Text] [Related]
8. [Drugs used in the therapy of peptic ulcer with special reference to H2 receptor blockaders]. De Natale G; De Natale F; Marino A Clin Ter; 1989 Apr; 129(1):3-16. PubMed ID: 2567647 [TBL] [Abstract][Full Text] [Related]
10. Acid suppression therapy: where do we go from here? Scarpignato C; Pelosini I; Di Mario F Dig Dis; 2006; 24(1-2):11-46. PubMed ID: 16699262 [TBL] [Abstract][Full Text] [Related]
11. Topically active drugs in the treatment of peptic ulcers. Focus on colloidal bismuth subcitrate and sucralfate. Bianchi Porro G; Parente F J Clin Gastroenterol; 1992 Apr; 14(3):192-8. PubMed ID: 1348753 [TBL] [Abstract][Full Text] [Related]
12. [Antacids in combination with other anti-ulcer agents]. Fritsch WP Z Gastroenterol; 1983 Mar; 21 Suppl():81-7. PubMed ID: 6134405 [TBL] [Abstract][Full Text] [Related]
13. Clinical importance of the new H2-antagonists. Walt RP Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():97-9. PubMed ID: 2566730 [TBL] [Abstract][Full Text] [Related]
14. Nonsteroidal anti-inflammatory drugs: add an anti-ulcer drug for patients at high risk only. Always limit the dose and duration of treatment with NSAIDs. Prescrire Int; 2011 Sep; 20(119):216-9. PubMed ID: 21954519 [TBL] [Abstract][Full Text] [Related]
15. A clinical approach to management of patients with non-steroidal anti-inflammatory gastropathy. Yeomans ND Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S89-92. PubMed ID: 10379475 [TBL] [Abstract][Full Text] [Related]
16. [Are proton pump inhibitors superior to H2 receptor antagonists within the scope of H. pylori eradication therapy? Meta analysis of current parallel group comparisons]. Holtmann G; Layer P; Goebell H Z Gastroenterol; 1996 May; 34(5):267-72. PubMed ID: 8686357 [TBL] [Abstract][Full Text] [Related]
17. Non-steroidal anti-inflammatory drug gastropathy: clinical results with H2 antagonists and proton pump inhibitors. Lazzaroni M; Bianchi Porro G Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S73-8. PubMed ID: 10379473 [TBL] [Abstract][Full Text] [Related]
18. Study of interaction of gastrointestinal agents in the presence of cytoprotective drugs. Part II. In vitro study on the adsorption of selected spasmolytic drugs on sucralfate. Pluta J; Grimling B Acta Pol Pharm; 2001; 58(6):473-9. PubMed ID: 12197622 [TBL] [Abstract][Full Text] [Related]
19. Newer H2-receptor antagonists. Clinical pharmacokinetics and drug interaction potential. Krishna DR; Klotz U Clin Pharmacokinet; 1988 Oct; 15(4):205-15. PubMed ID: 2903807 [TBL] [Abstract][Full Text] [Related]
20. Antacids and anticholinergics in the treatment of duodenal ulcer. Walan A Clin Gastroenterol; 1984 May; 13(2):473-99. PubMed ID: 6086186 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]